Key result
Platelet activating factor significantly augmented the vasocontractile response to noradrenaline in the presence of platelets, an effect alleviated by the 5-HT2 receptor antagonist ketanserin.
Why the study?
Does platelet activating factor (PAF) augment the vasocontractile response to noradrenaline in the presence of platelets in isolated rabbit ear arteries?
Does platelet activating factor (PAF) augment the vasocontractile response to noradrenaline in the presence of platelets in isolated rabbit ear arteries?
p-value: p=<0.05
PAF augments blood vessel contractility to noradrenaline through a platelet-dependent mechanism, likely involving 5-HT release rather than prostanoids.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for PAF in platelet-augmented vasoconstriction; requires human studies before clinical consideration.
T Michibayashi (1996) studied Vascular responsiveness. Platelet Activating Factor (PAF) vs. Platelet-rich plasma without PAF or modified normal Krebs' solution alone was evaluated on Vasocontractile response to noradrenaline (NA-R) (p=<0.05). Platelet activating factor significantly augmented the vasocontractile response to noradrenaline in the presence of platelets, an effect alleviated by the 5-HT2 receptor antagonist ketanserin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: